Clinical Trial

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

Study acronym: αHLA-G Exo-01
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-21; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT07219940
Lead Sponsor Shine-On Biomedical Co., Ltd.
Conditions Healthy Subjects, Exosome, Targeted Therapy
Enrollment 15 participants
Start Date 2025-12-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-26